- Home
- SYRE vs JMIA Comparison
SYRE vs JMIA Comparison
Compare SYRE & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- JMIA
- Stock Information
- Founded
- SYRE 2013
- JMIA 2012
- Country
- SYRE United States
- JMIA Germany
- Employees
- SYRE N/A
- JMIA N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- JMIA Catalog/Specialty Distribution
- Sector
- SYRE Health Care
- JMIA Consumer Discretionary
- Exchange
- SYRE Nasdaq
- JMIA Nasdaq
- Market Cap
- SYRE 1.1B
- JMIA 949.1M
- IPO Year
- SYRE 2016
- JMIA 2019
- Fundamental
- Price
- SYRE $17.38
- JMIA $7.88
- Analyst Decision
- SYRE Buy
- JMIA Hold
- Analyst Count
- SYRE 5
- JMIA 1
- Target Price
- SYRE $55.00
- JMIA $4.75
- AVG Volume (30 Days)
- SYRE 490.8K
- JMIA 5.6M
- Earning Date
- SYRE 08-05-2025
- JMIA 08-07-2025
- Dividend Yield
- SYRE N/A
- JMIA N/A
- EPS Growth
- SYRE N/A
- JMIA N/A
- EPS
- SYRE N/A
- JMIA N/A
- Revenue
- SYRE N/A
- JMIA $164,022,000.00
- Revenue This Year
- SYRE N/A
- JMIA $8.75
- Revenue Next Year
- SYRE N/A
- JMIA $9.21
- P/E Ratio
- SYRE N/A
- JMIA N/A
- Revenue Growth
- SYRE N/A
- JMIA N/A
- 52 Week Low
- SYRE $10.91
- JMIA $1.60
- 52 Week High
- SYRE $40.26
- JMIA $8.17
- Technical
- Relative Strength Index (RSI)
- SYRE 57.01
- JMIA 72.42
- Support Level
- SYRE $15.73
- JMIA $6.86
- Resistance Level
- SYRE $17.42
- JMIA $8.17
- Average True Range (ATR)
- SYRE 0.89
- JMIA 0.62
- MACD
- SYRE 0.07
- JMIA 0.09
- Stochastic Oscillator
- SYRE 86.50
- JMIA 91.83
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.